Damora Therapeutics, Inc.
Price
Key statistics
- Forward rate
- $0.00
- Yield
- 0.00%
- Payout ratio
- 0.00%
- Frequency
- Unknown
Damora Therapeutics, Inc. is a biopharmaceutical company focused on developing treatments for hematologic disorders, with an emphasis on mutant calreticulin-driven myeloproliferative neoplasms. Its current pipeline centers on DMR-001, an investigational monoclonal antibody therapy for essential thrombocythemia, alongside DMR-002 and DMR-003, which are designed to broaden coverage across mutCALR-driven disease biology. The company also develops GB3226, a small-molecule inhibitor targeting ENL-YEATS and FLT3 for acute myeloid leukemia. Damora Therapeutics concentrates on advancing targeted, disease-modifying therapies for blood cancers and related marrow disorders through a research-driven clinical development model. Founded in 2011 and headquartered in Waltham, Massachusetts, Damora Therapeutics operates in the biopharmaceutical sector as a developer of specialized therapies for patients with significant unmet medical needs.
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Ms. Jennifer A. Jarrett M.B.A.
- Employees
- 7
- Headquarters
- Waltham, MA, United States
- Website
- www.damoratx.com